RBC Capital Raises PT on Ocular Therapeutix (OCUL) to $24 Amid Solid Growth Trajectory

Ocular Therapeutix, Inc. (NASDAQ:OCUL) is one of the 15 stocks set to explode in 2026.

On November 5, 2025, RBC Capital raised its price target on Ocular Therapeutix, Inc. (NASDAQ:OCUL) from $17 to $24, while maintaining an “Outperform” rating.

The revised target was attributed to the company’s strong execution in its SOL-1 wet age-related macular degeneration (wAMD) superiority study. The study is on a solid trajectory for a first-quarter 2026 top-line readout. The investment firm cited patient retention and adherence going past 95%, no signs of safety concerns, and excess cash reserves as key growth drivers. The cash reserves now sit at approximately $790 million following a $445 million capital raise. Furthermore, RBC Capital sees Ocular Therapeutix, Inc. (NASDAQ:OCUL) potentially gaining significant market share in both wAMD and DR segments, expecting the company’s momentum to extend into diabetic retinopathy trials.

On the other hand, on November 4, 2025, Ocular Therapeutix, Inc. (NASDAQ:OCUL) released its Q3 2025 results. The quarter marked a reaffirmation of the company’s progress in its SOL-R trial, which achieved its randomization goal of 555 subjects. The company demonstrated disciplined trial design by expanding its AXPAXLI program across retinal diseases. The company maintains a financial runway into 2028 with a cash balance of $344.8 million, excluding net proceeds of $445 million from an underwritten offering of common shares.

Ocular Therapeutix, Inc. (NASDAQ:OCUL), an integrated biopharmaceutical company, develops innovative hydrogel-based therapies for treating retinal diseases.

While we acknowledge the potential of OCUL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Best Fortune 500 Stocks to Invest in Now and 13 Best Fortune 500 Stocks to Invest in Now.

Disclosure: None.